{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"210"}],"units":"Participants"}],"description":"Percentage of participants who do not experience disease relapse, disease progression, or death.","groups":[{"description":"Non-myeloablative haploidentical bone marrow transplant with a fludarabine, cyclophosphamide (Cy), TBI (total body irradiation) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.","id":"OG000","title":"Mini-haplo BMT"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}